An observational study in Obesity, Bariatric Surgery and Bariatric Surgery (Sleeve Gastrectomy ), sponsored by The Third Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by The Third Xiangya Hospital of Central South University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity, Morbid with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Obesity, Morbid · China.
Among the 10 studies in Obesity, Morbid with a site in China, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 9th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →4 of the 10 studies in Obesity, Morbid with a site in China are open now. Recruiting first, the newest first:
Yongtao Sun · Sites in China
Ages 18–60
Beijing Friendship Hospital · Sites in China
Ages 18–70
Yongtao Sun · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 60 across the 7 interventional studies, 138 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.
The Third Xiangya Hospital of Central South University has 1 study filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
2 of the studies in Obesity, Morbid with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712199Yongtao SunEffect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery | 2026-12-31 |
| NCT07135141Beijing Friendship HospitalMazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity, Morbid with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to establish a classification system for patients undergoing metabolic surgery for severe obesity by constructing a prospective cohort of 2,000 patients and collecting clinical and biological data at multiple time points before and after surgery. By analyzing clinical, laboratory, and multi-omics characteristics, the study will identify indicators associated with postoperative adverse events and develop a risk warning model using machine learning algorithms. Ultimately, an intelligent digital system will be developed based on the classification criteria and risk model, integrating surgical classification and risk alert functions to provide real-time feedback, supporting clinicians and patients in optimizing postoperative treatment and risk management.
Establishment of a Prospective Disease-Specific Follow-up Cohort of 2,000 Patients Based on the Following Inclusion and Exclusion Criteria
All participants will undergo metabolic surgery. A prospective, disease-specific follow-up cohort will be established, and baseline data will be collected. Patients will be followed up at multiple postoperative time points: days 3 and 7, and months 1, 3, 6, 12, and 24. Follow-up assessments will include the occurrence of postoperative complications and adverse events, as well as the degree of metabolic improvement and prognosis.
A multidimensional data platform will be used to integrate and analyze diverse indicators, identifying those strongly associated with postoperative adverse events. Clustering analysis will be applied to establish a classification system for patients undergoing metabolic surgery for severe obesity. Targeted assays will be performed on time-series biospecimens to identify novel risk biomarkers. A risk warning model will be constructed, validated, and evaluated. Finally, an intelligent digital system integrating patient classification and real-time risk alert functions will be developed to optimize long-term outcomes and enhance the precision and timeliness of classification and risk warning for healthcare professionals and patients.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.
Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients undergoing bariatric/metabolic surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet the clinical indications for bariatric/metabolic surgery;
Exclusion Criteria:
① Patients with conditions affecting the immune or metabolic systems (e.g., endocrine disorders such as untreated hypothyroidism/hyperthyroidism, cancer);
Patients with renal or hepatic impairment;
Patients who have taken medications that may affect metabolism within the past 3 months (e.g., weight-loss drugs, asthma medications, psychiatric medications, );
Patients who have previously undergone bariatric surgery and are undergoing revisional surgery; ⑤ Patients with psychiatric disorders, especially those with comorbid behavioral or personality disorders (e.g., binge eating disorder);
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of Participants Stratified into Distinct Clusters Using Unsupervised Clustering Algorithm Based on BMI, Comorbidity Count, Inflammatory Markers, and Proteomics Profiles
Participants will be stratified at baseline using an unsupervised clustering algorithm (e.g., k-means) based on the following input variables:(1)Body mass index (BMI, kg/m²);(2)Comorbidity count (number of chronic diseases at enrollment);(3)Inflammatory markers (e.g., CRP in mg/L, IL-6 in pg/mL);(4)Proteomics features (relative expression intensity from LC-MS) The clustering procedure will produce a categorical variable assigning each participant to one of 3-5 data-driven subtypes. The total number of participants in each subtype group will be reported.
Time frame: From enrollment to the end of follow-up at 2 years
Accuracy, Sensitivity, and Specificity of the Postoperative Risk Prediction Model for Adverse Outcomes
Model performance will be assessed for predicting postoperative adverse outcomes within 12 months after bariatric surgery. Predictors include demographic data, intraoperative parameters, early postoperative recovery data, and stratification subtype. Model discrimination will be evaluated using area under the receiver operating characteristic curve (AUC-ROC), and calibration will be assessed with calibration plots and Hosmer-Lemeshow test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) will be reported using confusion matrix analysis in internal validation (e.g., bootstrapping or 10-fold cross-validation).
Time frame: Up to 24 months after surgery
User Satisfaction Score of the Digital Postoperative Management System Measured by System Usability Scale (SUS)
User experience and satisfaction with the digital management system will be evaluated using the validated 10-item System Usability Scale (SUS). SUS scores range from 0 to 100, with higher scores indicating greater usability. Both patients and clinical staff will be surveyed at 3 months post-deployment.
Time frame: At 24 months after initiation of digital system use
Plan to share: Undecided — Undecided. Data sharing is currently under consideration. The decision will depend on institutional policy, ethical review board approval, and the establishment of appropriate data-use agreements to protect participant confidentiality.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2035, 128 months after the start.
Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 128 months is above that.
Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Third Xiangya Hospital of Central South University